CMEK162X2201


Protocolnummer:

Ziekenhuizen:
NKI / A.v.L ziekenhuis Amsterdam
RadboudUMC Nijmegen

Titel:
A phase ll, open-label study to assess the safety and effficacy of oral MEK 162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harbouring BRAFV600E or NRAS mutations.

Behandeling:
oral MEK-inhibitor

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:
In: advanced melanoma, > 18, BRAF V600E or NRAS mutation, ECOG 0-2, measurable disease (RECIST), LVEF>50 %. Ex: prior therapy with a MEK inhibitor, history or current central serous retinopathy or retinal vein occlusion, history or evidence of acute coronary syndromes, biological therapy within 4 weeks prior to starting study drug.

Contactpersoon:
Carla van Herpen

Alle melanoom trials